OCUL Ocular Therapeutix Inc.

5.33
-0.31  -6%
Previous Close 5.64
Open 5.64
Price To Book 4.8
Market Cap 219038333
Shares 41,095,372
Volume 515,735
Short Ratio
Av. Daily Volume 504,743

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181225062
  2. 8-K - Current report 181212808
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166443
  4. 8-K - Current report 181166361
  5. CT ORDER - Confidential treatment order 181130341

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released November 14, 2016. Primary endpoints met.
DEXTENZA
Post-surgical ocular inflammation and pain
Phase 3 trial did not meet primary endpoint - June 2016. Additional Phase 3 trial to be initiated pending data from a non-significant risk device study to be initiated in 2017.
DEXTENZA
Allergic conjunctivitis
Phase 3 data due 1H 2019.
OTX-TP
Glaucoma and ocular hypertension
FDA approval announced December 3, 2018.
DEXTENZA
Ocular inflammation and pain following cataract surgery
Phase 2 complete. Assessing plans forward.
DEXTENZA
Dry Eye Disease
Phase 1 data due 1H 2019.
OTX-TIC
Glaucoma and ocular hypertension

Latest News

  1. Ocular Therapeutix™ Announces the Hiring of Chad Brines, Vice President, Sales
  2. Options Traders Expect Huge Moves in Ocular Therapeutix (OCUL) Stock
  3. CORRECTING and REPLACING Ocular Therapeutix™ Announces FDA Approval of DEXTENZA® for the Treatment of Ocular Pain Following Ophthalmic Surgery
  4. Ocular Therapeutix™ to Present at the 30th Annual Piper Jaffray Healthcare Conference
  5. Edited Transcript of OCUL earnings conference call or presentation 7-Nov-18 9:30pm GMT
  6. H.C. Wainwright Sees over 80% Upside Potential for These Three Biotech Stocks
  7. Recent Analysis Shows Clovis Oncology, Evertec, Etsy, Ring Energy, Ocular Therapeutix, and Destination Maternity Market Influences — Renewed Outlook, Key Drivers of Growth
  8. Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates
  9. Ocular Therapeutix: 3Q Earnings Snapshot
  10. Ocular Therapeutix™ Reports Third Quarter 2018 Financial Results and Business Update
  11. Ocular Therapeutix™ To Report Third Quarter 2018 Financial Results
  12. Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know
  13. Ocular Therapeutix (OCUL): ReSure Warning Letter Insignificant to Pipeline, Says Analyst
  14. Ocular Therapeutix stock drops 10% after FDA warning letter
  15. Ocular Therapeutix™ Receives FDA Warning Letter Related to ReSure® Sealant
  16. Investor Expectations to Drive Momentum within Teradata, Liberty TripAdvisor, CPI Card Group, Cara Therapeutics, Ocular Therapeutix, and G-III Apparel Group, LTD — Discovering Underlying Factors of Influence
  17. Who Owns Ocular Therapeutix Inc (NASDAQ:OCUL)?
  18. Why Analysts See Solid Upside Potential for Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX), and AcelRx (ACRX)
  19. Ocular Therapeutix™ to Present at the 2018 Cantor Global Healthcare Conference
  20. Edited Transcript of OCUL earnings conference call or presentation 7-Aug-18 8:30pm GMT

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181225062
  2. 8-K - Current report 181212808
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166443
  4. 8-K - Current report 181166361
  5. CT ORDER - Confidential treatment order 181130341
  6. 8-K - Current report 181129315
  7. 8-K - Current report 181095926
  8. 8-K - Current report 181077857
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 18998316
  10. 8-K - Current report 18997974